Cingulate(CING) - 2024 Q1 - Quarterly Report

As of March 31, 2024, we had cash and cash equivalents of $1.1 million. We believe our cash will satisfy our capital needs through late in the second quarter of 2024 under our current business plan. In addition, in order to achieve the filing of our NDA for CTx-1301 in the first half of 2025 for potential FDA approval, we believe that we will need approximately$11-13 million of additional capital, which is an increase of approximately $2 million from the previously disclosed amount. This increase is relate ...